Arca Biopharma Inc - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
ABIO Nasdaq 2834 http://arcabio.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Arca Biopharma Inc

Christopher Graybill Joins ARCA as Vice President, Clinical Development - May 5th, 2021 8:05 pm
ARCA biopharma Announces C. Jeff Dekker to be Appointed Chief Financial Officer - May 3rd, 2021 8:30 pm
ARCA biopharma Announces 2020 Financial Results and Provides Corporate Update - Mar 18th, 2021 8:30 pm
Here's Why We're Not Too Worried About ARCA biopharma's (NASDAQ:ABIO) Cash Burn Situation - Feb 13th, 2021 6:09 am
ARCA biopharma Announces First Patients Enrolled in ASPEN-COVID-19 Phase 2b Clinical Trial Evaluating rNAPc2 (AB201) as a Potential Treatment for COVID-19 - Dec 15th, 2020 1:30 pm
ARCA biopharma Announces Location Change for 2020 Annual Meeting of Stockholders - Dec 9th, 2020 10:40 pm
AB201 Development as a Potential Treatment for COVID-19 Receives U.S. FDA Fast Track Designation - Nov 23rd, 2020 1:30 pm
ARCA biopharma Announces Third Quarter 2020 Financial Results and Provides Corporate Update - Nov 2nd, 2020 1:30 pm
ARCA biopharma Announces FDA Approval of IND Application for AB201 as a Potential Treatment for COVID-19 - Oct 7th, 2020 12:30 pm
ARCA biopharma Announces Promotion of Chief Medical Officer and Vice President, Regulatory Affairs & Quality - Oct 5th, 2020 8:30 pm
ARCA biopharma Announces Submission of IND Application to U.S. FDA for AB201 as a Potential Treatment for COVID-19 - Sep 21st, 2020 12:00 pm
We Think ARCA biopharma (NASDAQ:ABIO) Can Afford To Drive Business Growth - Aug 17th, 2020 12:49 pm
ARCA Biopharma Announces Completion of FDA Pre-IND Consultation Under Coronavirus Treatment Acceleration Program for AB201 as a Potential Treatment for Severe COVID-19 - Aug 12th, 2020 12:00 pm
Arca Biopharma Announces Second Quarter 2020 Financial Results and Provides Corporate Update - Aug 5th, 2020 8:15 pm
SARS-CoV-2 Cell Entry Mechanisms in Intact Human Heart Published in JACC: Basic to Translational Science by University of Colorado Anschutz Medical Campus and ARCA biopharma Investigators - Jul 7th, 2020 12:30 pm
ARCA biopharma Announces Closing of $6.1 Million Registered Direct Offering - Jun 3rd, 2020 1:56 pm
Biotech Stock Roundup: GILD's Coronavirus Drug Update, NTLA-REGN Deal & More - Jun 3rd, 2020 1:56 pm
ARCA Biopharma Announces $9.4 Million Registered Direct Offering - Jun 1st, 2020 12:20 pm
A Mighty May: Over $200,000 In Gross Profits - May 29th, 2020 4:24 pm
Company News for May 29, 2020 - May 29th, 2020 1:59 pm